MEDIBANK PRIVATE LIMITED (MPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MPL

MPL - MEDIBANK PRIVATE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Debt/EBITDA: N/A
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Medibank Private is the largest Australian private health insurance provider. Previously an Australian Government business enterprise, established by the Whitlam government in 1975, it was privatised in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.90

05 Jun
2025

0.020

OPEN

$4.86

0.41%

HIGH

$4.90

6,093,656

LOW

$4.85

TARGET
$4.67 -4.7% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AUB . CVW . FCL . GDG . HLI . IAG . NHF . NOL . QBE . SDF . SUN . TWR .
FNARENA'S MARKET CONSENSUS FORECASTS
MPL: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 17.9 22.1 xxx
DPS (cps) xxx 16.6 17.4 xxx
EPS Growth xxx - 3.7% 23.5% xxx
DPS Growth xxx 13.7% 4.6% xxx
PE Ratio xxx N/A 22.0 xxx
Dividend Yield xxx N/A 3.6% xxx
Div Pay Ratio(%) xxx 92.8% 78.6% xxx

Dividend yield today if purchased 3 years ago: 5.22%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.42

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 9.4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx17.9
DPS All xxxxxxxxxxxxxxx16.6
Sales/Revenue xxxxxxxxxxxxxxx8,021.6 M
Book Value Per Share xxxxxxxxxxxxxxx83.7
Net Operating Cash Flow xxxxxxxxxxxxxxx988.4 M
Net Profit Margin xxxxxxxxxxxxxxx6.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx22.44 %
Return on Invested Capital xxxxxxxxxxxxxxx21.57 %
Return on Assets xxxxxxxxxxxxxxx10.85 %
Return on Equity xxxxxxxxxxxxxxx22.44 %
Return on Total Capital xxxxxxxxxxxxxxx31.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx554.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx67 M
Long Term Debt xxxxxxxxxxxxxxx152 M
Total Debt xxxxxxxxxxxxxxx218 M
Goodwill - Gross xxxxxxxxxxxxxxx402 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx691 M
Price To Book Value xxxxxxxxxxxxxxx4.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.72 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx385 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx3,060 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

18/03/2025

3

Neutral

$4.85

-1.02%

Citi sees approved rate increases for private health insurers (PHIs) as better than expected, with claims inflation currently under control.

The broker notes potential risks from political pressure which could alter this dynamic.

Citi expects strong profitability for Medibank Private over the next 18 months but maintains a Neutral rating and $4.85 target.

FORECAST
Citi forecasts a full year FY25 dividend of 18.20 cents and EPS of 24.20 cents.
Citi forecasts a full year FY26 dividend of 19.80 cents and EPS of 25.50 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

13/05/2025

3

Neutral

$4.45

-9.18%

Jarden raises its target price to $4.45 from $4.30 for Medibank Private and retains a Neutral rating, suggesting the earnings outlook is now reflected in the share price.

Medibank’s unit growth in the resident segment matched system growth in the March quarter, with accelerating momentum in the non-resident segment, highlight the analysts.  

Claims inflation appears to be easing, aided by softer extras claims, favourable age mix, and in-line hospital indexation, explains the broker, though the guidance range of 2.4-2.6% for FY25 remains unchanged.

Jarden raises its FY25-FY27 EPS forecasts by up to 4.1%, citing stronger unit growth and reduced claims pressures, while adjusting 2H25 unit growth expectations to 2% for residents and 15% for non-residents.

FORECAST
Jarden forecasts a full year FY25 dividend of 17.80 cents and EPS of 22.30 cents.
Jarden forecasts a full year FY26 dividend of 18.70 cents and EPS of 23.10 cents.
Access Extra Coverage Research History >

MPL STOCK CHART

FNArena News on MPL

1
Rudi’s View: NextDC, QBE, Superloop & Woodside

Jun 05 2025 - Rudi's View
2
Rudi’s View: The Contrarians’ View

May 29 2025 - Rudi's View
3
Rudi’s View: Rate Cut Winners & AI Beneficiaries

May 22 2025 - Rudi's View
4
Rudi’s View: Is Buy The Dip Changing Markets?

May 21 2025 - Rudi's View
5
Rudi’s View: 30 For ’30 & Best Buy Convictions

May 15 2025 - Rudi's View

Latest Insurance News

1
Insurers To Pamper Shareholders With Buybacks

Jan 24 2025 - Australia
2
IAG Shares Breaking Out

Jan 21 2025 - Technicals
3
ESG Focus: The Little Big Things – 21-11-2024

Nov 21 2024 - ESG Focus
4
New-Look Suncorp Ready To Rumble

Nov 14 2024 - Australia
5
Steadfast’s Long March

Jul 02 2024 - Australia
6
AUB Group Shares Poised For Break-Out

Jun 13 2024 - Technicals
7
SMSFundamentals: Older People Are Life Insurers’ Future Challenge

Oct 26 2023 - SMSFundamentals
8
Australian Insurers And The Weather

Oct 19 2023 - Feature Stories
9
Steadfast Group’s US Entry Full Of Promise

Oct 11 2023 - Australia
10
Pros And Cons Of Insurance Companies

Aug 02 2023 - Australia